Background
==========

BRCA1 and cyclin D~1~are both essential for normal breast development and mutation or aberration of their expression is associated with breast cancer \[[@B1],[@B2]\]. Cyclin D~1~is best known as a G~1~cyclin where it regulates the G~1~to S phase transition by acting as a rate-limiting subunit of CDK4/6 kinase activity. More recently, however, Stacey has demonstrated that cyclin D~1~levels in G~2~/M determine whether a cell continues to proliferate or exits the cell cycle \[[@B3]\]. The majority of BRCA1 in the cell is bound to BARD1 through their N-terminal RING domains. Hetero-dimerization is essential for the stability and correct localization of the complex and confers ubiquitin ligase activity to BRCA1. The importance of the ligase activity of BRCA1 to breast cancer development is inferred from the fact that N-terminal disease-associated mutations are proposed to reduce ligase activity \[[@B4]\].

Methods
=======

Protein--protein interactions were demonstrated using yeast-two-hybrid and coimmunoprecipitation. Protein levels were altered through overexpression, siRNA and antisense technology. The effect of proteasome inhibitors and cycloheximide treatment was also examined.

Results
=======

We initially identified cyclin D~1~as a binding partner of BARD1 in a yeast-two-hybrid screen and defined the minimal binding region as the N-terminus of BARD1. This interaction was confirmed *in vivo*by coimmunoprecipitation. The N-terminus of BARD1 also binds BRCA1 and imparts ubiquitin ligase activity to the complex. Covalent modification of proteins with ubiquitin is a common regulatory mechanism in eukaryotic cells. Traditionally, polyubiquitin chains linked through lysine 48 target proteins for degradation by the 26 S proteasome. We have demonstrated that cyclin D~1~protein levels are inversely related to BRCA1 and BARD1 levels in several model systems. Furthermore, regulation of cyclin D~1~levels occurs through a post-transcriptional mechanism and requires the ligase activity of BRCA1. Interestingly, this phenomenon is cell-cycle regulated, occurring in G~2~/M.

Conclusion
==========

We propose that cyclin D~1~is a potential substrate for BRCA1 ubiquitination and that this targets cyclin D~1~for proteasomal-mediated degradation. Future work will focus on ascertaining the functional consequence of cyclin D~1~regulation by the BRCA1--BARD1 complex; in particular, the impact of BRCA1, mediated through regulation of cyclin D~1~, on the proliferation versus differentiation decision.
